Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: Post hoc analysis of the ASSET-K study

Table 2 Characteristics of the 831 patients stratified into three age groups

	Age group			P value
	<65 years	65–74 years	≥75 years
n (%)	423 (50.9)	282 (33.9)	126 (15.2)
Age (years)	54.8 ± 7.8	69.4 ± 2.8	78.2 ± 3.0	<0.0001^*
Sex (male/female)	271/152	141/141	57/69	<0.0001^†
Duration of diabetes (years)	9.3 ± 5.9	14.7 ± 8.8	16.8 ± 9.9	<0.0001^*
Body mass index	25.5 ± 4.6	23.5 ± 3.5	23.7 ± 3.3	<0.0001^*
Concomitant medications (%)
Sulfonylureas	61.9	67.4	61.1	0.2763^†
Biguanides	56.7	50.0	34.9	<0.0001^†
Thiazolidinediones	27.2	22.3	22.2	0.2764^†
Alpha-glucosidase inhibitors	9.2	8.9	11.9	0.5763^†

ISSN: 1472-6823